3 Crashing Biotechs: Is 1 a Buy?

Here's why Aegerion (AEGR), Vivus (VVUS), and Exelixis (EXEL) are healthcare's worst performers this year.

Jul 11, 2014 at 5:00PM

Healthcare has been on a run this year, but not all of the companies in the sector have gone higher. These three have all dropped by more than a third this year. Given their dramatic sell-off, let's take a closer look at what's behind the drop in Aegerion (NASDAQ:AEGR), Vivus (NASDAQ:VVUS), and Exelixis (NASDAQ:EXEL), and see whether any of them offer an opportunity.


Source: Aegerion

Not fast enough
After peaking at nearly $100 per share last fall, shares in Aegerion have tumbled more than 50% this year. Expectations were high when Aegerion won approval for Juxtapid in December 2012. The drug, used to treat homozygous familial hypercholesterolemia, or HoFH, carries a sky high price tag of roughly $235,000 per year, making it one of the most expensive treatments on the planet.

A high price and widespread enthusiasm for orphan drugs overall drove shares to lofty levels that have proven tough to justify. Sales of Juxtapid, which competes with Sanofi and Isis Pharmaceuticals' Kynamro, totaled $48.5 million last year and $27 million in the first quarter.

Although its first-quarter sales growth was solid, results were shy of expectations, and that forced Aegerion to lower its full-year sales outlook to between $180 million and $200 million. As a result, investors headed for the exits.

However, now that shares have been cut in half, valuation is starting to get more intriguing. With a market cap of just $850 million, shares are trading at between four and five times sales and, while that's not cheap, it's not out-of-control expensive either. The company isn't expected to turn a profit until 2015, but analysts continue to think that Aegerion could generate more than $5 per share in EPS by 2017. If it can deliver on that lofty earnings outlook, shares would be undeniably cheap at these levels, but that's a big if.

AEGR EPS Estimates for Current and Next 3 Fiscal Years Chart

AEGR EPS Estimates for Current and Next 3 Fiscal Years data by YCharts.

Thinning patience
Lackluster sales for Vivus' highly anticipated obesity drug Qsymia are to blame for Vivus' ongoing slide from its peak near $30 per share back in 2012. So far this year, shares have fallen 45% to less than $5.

VVUS Chart

VVUS data by YCharts.

Expectations were high leading up to Qsymia's approval in 2012. Thanks to estimates that pegged as many as a third of Americans as obese, analysts had attached billion dollar blockbuster potential to Qsymia.

But, despite those bullish predictions, demand has been slow to develop. That lack of demand could stem from the reluctance of doctors to prescribe the drug given that one of Qysimia's two active ingredients is phentermine, a drug responsible for Wyeth's $13 billion fen-phen settlement.

Regardless of the reason, the reality is that sales remain anemic at just $9 million in the first quarter. That gives the company a $36 million annualized sales run rate that still makes the company look expensive, even with a market cap of just $500 million.


Source: Exelixis

Waiting, waiting, waiting
Exelixis shares are down 45% this year; however, that entire drop is tied to just one month: March. It was in March that independent monitors of Exelixis phase 3 prostate cancer trial said the trial should continue rather than be halted early. Investors hoping for an early end to the trial, similar to Medivation and Astellas' phase 3 trial for Xtandi, took that as a sign that Exelixis wasn't the breakthrough drug they had previously anticipated.

That could prove true... or not. Investors won't know for months. Because the trial is continuing, we can assume the drug's safety isn't in question; but whether its efficacy is good enough to win away share from Johnson & Johnson's $2 billion a year Zytiga, or Medivation and Astellas' fast-growing Xtandi, remains to be seen.

Investors should get top-line data from the trial later this year; but in the meantime, Exelixis is burning through cash. Sales of Cometriq in medullary thyroid cancer, or MTC, totaled just $5 million in Q1, yet the company spent more than $54 million on R&D, and nearly $15 million on SG&A in the quarter.

Fool-worthy final thoughts
Risk-tolerant investors may find that Aegerion is the most intriguing of the three. Even though the company has cut its guidance, Juxtapid remains on pace to post robust sales growth this year. However, that growth is vital given that Aegerion's pipeline is nonexistent.

While hope springs eternal for weight-control drugs, the market has yet to embrace Vivus' drug and, until it does, I'm staying away. Meanwhile, Exelixis' Cometriq may be intriguing, and may have legs in other indications beyond prostate cancer; but buyer beware until I can feel confident that sales are going to offset its massive appetite for spending.

Leaked: Here's a blockbuster idea with far fewer question marks
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Todd Campbell owns shares of Exelixis. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Exelixis. The Motley Fool owns shares of Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers